Trabikibart (CSL311), a βc-specific, fully human monoclonal antibody, specifically binds to the cytokine-binding epitope of the human βc receptor with picomolar affinity. It potently inhibits the collective impact of IL-3, GM-CSF, and IL-5 on eosinophil survival, underscoring its potential in chronic inflammatory diseases research [1].